Gene targeting by single-stranded oligodeoxyribonucleotides (ssODNs) is a promising technique for introducing site-specific sequence alterations without affecting the genomic organization of the target locus. Here, we discuss the significant progress that has been made over the last 5 years in unraveling the mechanisms and reaction parameters underlying ssODN-mediated gene targeting. We will specifically focus on ssODN-mediated gene targeting in murine embryonic stem cells (ESCs) and the impact of the DNA mismatch repair (MMR) system on the targeting process. Implications of novel findings for routine application of ssODN-mediated gene targeting and challenges that need to be overcome for future therapeutic applications are highlighted.
INTRODUCTION
With the advance of human genome sequencing many small DNA sequence variations in the human population have been identified. The consequences of these sequence variations are often difficult to predict, in some cases variations may represent neutral polymorphisms, whereas in other they may be deleterious and cause disease. Site-specific gene modification provides a powerful tool to recreate and functionally characterize sequence variants in an appropriate cell type in order to distinguish between polymorphisms and truly pathogenic mutations. Furthermore, permanent correction of a defective gene at its natural chromosomal location may be the ideal treatment for human genetic disease.
Several strategies have been developed for the generation of sitespecific sequence alterations. Gene targeting through homologous recombination requires the design and construction of a targeting vector that is homologous to the target locus. 1, 2 The desired genetic alteration is integrated into the gene of interest together with a selectable marker gene, which is subsequently removed by Cre/ lox-mediated recombination. 3, 4 This procedure requires multiple rounds of selection and clonal purification of the modified cells, which can be laborious and time-consuming. More recently, subtle gene modification has been achieved by the use of zinc-finger nucleases that are engineered to introduce site-specific doublestranded DNA breaks in the genome. Homology-directed repair of the double-stranded DNA break using a linear double-stranded donor DNA fragment carrying the desired alteration may be accompanied by site-specific alteration of the genome. 5, 6 Although this approach can be remarkably effective (single base changes have been obtained in±20% of exposed cells), an obvious obstacle is that zinc-finger nucleases need to be designed and constructed for every specific location to be modified. Zinc-finger nucleases-directed gene modification may therefore be particularly useful to generate a series of substitutions at the same location or, with a view on gene therapy, to repair a frequently occurring mutation.
Here, we discuss yet an alternative approach for subtle gene modification that makes use of short synthetic single-stranded oligodeoxyribonucleotides (ssODNs), which upon entry into cells can introduce the desired alteration into the genome. A typical ssODN consists of several dozens of nucleotides of which the sequence is identical to a specific target locus except for the one or few nucleotides comprising the desired alteration. 7 We will highlight recent advances that have been made to uncover the mechanism of ssODN-mediated gene targeting, with a focus on its application in murine embryonic stem cells (ESCs).
Site-specific sequence alterations have successfully been introduced into ESC using ssODN of 35-40 nucleotides and modified ESC lines have been used to generate mouse models that accurately mimic human inherited disease. 8, 9 Unfortunately, targeting frequencies in mouse ESCs range from 10 À7 to 10 À4 , which is relatively low compared with those found in other cell types. [10] [11] [12] [13] [14] A better understanding of the reaction parameters governing ssODN-mediated gene targeting in ESCs 15, 16 is imperative to improve the applicability of the technique. Although different DNA repair pathways may impinge on the targeting process, we will particularly address the role of the DNA mismatch repair (MMR) system that imposes a strong barrier to effective application of ssODN-mediated gene targeting. Lastly, we discuss the challenges that need to be overcome before ssODNmediated gene targeting may be exploited for gene therapeutic purposes.
PROGRESS

Mechanistic models for ssODN-mediated gene targeting
Based on work on Escherichia coli and a variety of mammalian cell systems, several models have been proposed for the mechanism of ssODN-mediated gene targeting. 17 According to the repair-dependent model ( Figure 1 , Model I), pairing between the ssODN and its chromosomal complement leads to the formation of a displacement loop. DNA repair proteins would then introduce the desired base alteration into the chromosomal DNA strand using the ssODN as a template. Support for such a model was recently obtained in murine myoblasts. 18 In alternative models (Figure 1 ), the ssODN becomes physically integrated into the genome within the context of either a replication fork (Model II) or a displacement loop (Model III).
A distinction between the ssODN serving as a template for repair or becoming physically incorporated into the genome, can be made by using an EGFP reporter gene that allows early detection of gene restoration events. Physical incorporation of an anti-sense ssODN (complementary to the non-transcribed strand) would modify the transcribed strand, immediately giving rise to green fluorescent cells (Figure 1 , Model II or III). In contrast, incorporation of a sense ssODN would necessitate a second round of replication for the modification to become introduced into the transcribed strand. In the repair-dependent model, the situation would be reversed. In ESCs, the appearance of green fluorescent cells obtained with sense ssODNs lagged 1 day behind that obtained with anti-sense ssODNs, which indicates that the ssODN had been physically incorporated. 19 Over the past few years, it has become evident that DNA replication is the predominant cellular process underlying ssODN-mediated gene targeting in bacteria, [20] [21] [22] yeast 23, 24 and various mammalian cell lines including ESCs. 16, 25, 26 According to this model, the ssODN anneals to its chromosomal complement when this becomes exposed as singlestranded DNA within the context of a replication fork. Upon annealing, the ssODN can serve as a primer for DNA synthesis to form a 'pseudo' Okazaki fragment, resulting in physical incorporation of the ssODN into the nascent DNA strand. The finding that S phase appeared to be the preferred cell cycle phase for gene correction provided strong support for this model. Increasing the number of cells that progressed through S phase or slowing down replication fork progression during ssODN exposure resulted in elevated targeting frequencies in various mammalian cell lines. [25] [26] [27] The discontinuous nature of lagging strand DNA synthesis may expose more ssDNA regions and thus facilitate ssODN annealing. Indeed, studies in E. coli demonstrated that ssODNs corresponding in sequence to the lagging strand consistently performed better, irrespective of the direction of transcription, thereby establishing a direct link between ssODN polarity and the direction of replication through the target locus. 14, 20, 21, 28, 29 In mammalian cells, a direct link between the polarity of the ssODN and the direction of replication could not be established, 16, 30 as the direction of the replication fork through the target locus is difficult to determine and may vary because of the firing of different origins in subsequent cell cycles.
Although the role of DNA replication seems firmly established, also replication-independent integration of ssODNs has been proposed ( Figure 1 , Model III). Igoucheva et al. 31 suggested a model based on the differential accessibility of the DNA strands during transcription to explain the often-observed strand bias in favor of anti-sense ssODNs. 10, 11, 13, 27, 30 During transcription, ssDNA regions are provided that facilitates annealing of complementary ssODN. The increased accessibility of the non-transcribed strand could promote annealing of anti-sense ssODNs, whereas the RNA polymerase activity on the transcribed strand could lead to displacement of sense ssODNs. Upon binding of the ssODN in a displacement loop structure, endonucleases may excise the transcribed DNA strand followed by integration of the ssODN into the target locus ( Figure 1 , Model III). In inducible episomal reporter systems in E. coli, 28, 32 Saccharomyces cerevisiae, 33 and mammalian cells, 31 increased transcriptional activity improved the overall frequency of ssODN-mediated gene targeting. However, this effect could not be recapitulated in chromosomally located reporter systems, 16, 23 indicating that in chromosomal targeting integration of the ssODN occurs through mechanisms that are largely independent of transcriptional activity at the target locus. Besides DNA replication and transcription, DNA repair proteins involved in homologous recombination, [34] [35] [36] and nucleotide excision repair, 37 have also been implicated in the targeting process. However, RNAi-mediated suppression of homologous recombination or nucleotide excision repair protein levels did not affect the targeting frequency in ESCs. 16 Role of the DNA mismatch repair system in ssODN-mediated gene targeting When the ssODN anneals to its single-stranded complement, DNA mismatches are formed that may be recognized by the DNA MMR system. Therefore, much work has been devoted to elucidating the potential role of DNA MMR in ssODN-directed gene modification. In eukaryotic cells, mismatches can be recognized by either one of two heterodimeric protein complexes: MSH2/MSH6 (MutSa) and MSH2/MSH3 (MutSb) that have specific and partially redundant mismatch recognition capacities (see Jiricny 38 and Kunz et al. 39 for review). The MSH2/MSH6 heterodimer mainly recognizes single base-base mismatches and small loops of one or two nucleotides, whereas the MSH2/MSH3 complex has more affinity for larger loops of two to five unpaired nucleotides. Upon mismatch binding, the MutS homolog (MSH) heterodimeric complexes activate a eukaryotic MutL homolog, consisting of the MLH1 protein complexed with PMS2 (MutLa), PMS1 (MutLb) or MLH3 (MutLg) (Figure 2 ). Of these complexes, MutLa has the most important role in MMR and functions to coordinate the events from mismatch binding by the MutS homologs to degradation and resynthesis of the nascent DNA strand. Nucleolytic degradation is initiated at a gap or nick that is generated either 5¢ or 3¢ of the mismatched nucleotide. In prokaryotes, strand discrimination is mediated by the MutS/MutL-activated MutH endonuclease, which generates a nick into the transiently unmethylated nascent DNA strand. In eukaryotic MMR, the endonuclease activity of MutLa may be responsible for inducing nicks into the discontinuous DNA strand. 40 Strand discontinuities in the leading strand and the Okazaki fragments in the lagging strand may serve as the signal that targets the newly synthesized strand for MMR. The MutH-or MutLa-induced nicks provide entry points for the MutS/ MSH-activated exonuclease ExoI that removes the DNA strand carrying the mismatch in a 5¢-3¢ direction. The resulting single-stranded gap is stabilized by replication protein A. Once the mismatch is removed, ExoI activity is inhibited and DNA polymerases are activated to fill the gap. Repair synthesis is completed when DNA ligase I seals the remaining nick. In addition to the MutS and MutL complexes, other factors of the replication machinery may have a role in coordinating MMR. The homotrimeric sliding clamp proliferating cell nuclear antigen is loaded onto the 3¢ ends of newly synthesized DNA by replication factor C, where it functions as a processivity factor for the replicative polymerases. In eukaryotes, proliferating cell nuclear antigen has a central role in targeting the MMR proteins to the replication fork, but is also involved in the mismatch recognition and DNA synthesis steps in MMR (Figure 2 ). Besides the correction of DNA polymerase errors during replication, the MMR system also prevents recombination between homologous but non-identical sequences (homeologous recombination). 41 The involvement of MMR in ssODN-mediated gene targeting has been studied in various systems giving different and even opposing results. Early models for ssODN-mediated gene targeting proposed that the ssODN annealed to its chromosomal complement and served as a template for repair of this chromosomal DNA strand ( Figure 1 , Model I; see also Andersen et al. 42 and Liu et al. 43 for review). As chimeric RNA/DNA oligonucleotides exhibited reduced gene repair frequencies in human cell-free extracts lacking hMSH2 protein, 44 it was postulated that the MMR proteins were responsible for copying MutSa mainly recognizes single base-base mismatches and small loops of one or two nucleotides, whereas MutSb has more affinity for larger loops of two-five unpaired nucleotides. Upon mismatch binding and recruitment of the MLH1/PMS2 heterodimer (MutLa), the complex undergoes an ATPdriven conformational switch, which allows sliding away from the mismatch. The MutSa-or MutSb-activated exonuclease ExoI subsequently degrades the newly synthesized DNA strand containing the ssODN-induced mismatch in a 5¢-3¢ direction. Once the mismatch is removed, ExoI activity is inhibited and DNA polymerases are activated to fill the gap. PCNA and RFC have an important role in coordinating the mismatch recognition and DNA synthesis steps. Repair synthesis is completed when DNA ligase I seals the remaining nicks.
Oligonucleotide-directed gene modification in mouse embryonic stem cells M Aarts and H te Riele the sequence alteration from the ssODN to the chromosomal DNA strand. Consistent with this model, correction of a chromosomal reporter gene in yeast was 10-fold less efficient in the absence of Msh2p. 45 However, the proposed model is difficult to reconcile with the strand specificity of the MMR system: MMR proteins only act on the newly synthesized DNA strand, using the parental DNA strand as a template. Furthermore, in cell-free extracts derived from yeast and mouse embryonic fibroblasts, the efficacy of gene repair was not affected or even slightly increased upon MMR deficiency, 46,47 whereas episomal targeting frequencies in mouse embryonic fibroblasts were not significantly altered by Msh2-deficiency. 37 Although 9, 48 Consistently, inactivation of the MMR pathway in E. coli through deletion of mutS, mutL or mutH enhanced the targeting frequency 2-to several 100-fold. 21, 28, 29, 32 Although the suppressive effect of the MMR system has been most extensively studied in E. coli and mouse ESCs, MMR was also found to impose a significant barrier to ssODN-mediated gene targeting in human cell lines (Table 1) .
Suppression by MMR depends on the type of sequence alteration
The specific repair and recognition capacities of the MSH2/MSH6 and MSH2/MSH3 protein complexes could be exploited to allow the introduction of specific sequence alterations in mouse ESCs ( Table 2) . Ablation of both heterodimeric MutS complexes by deletion of the Msh2 gene allowed effective introduction of 1-, 2-, 3-and 4-nt substitutions, as well as +1 and +4 nt insertions. 48 Deletion of the Msh3 gene only eliminates the MutSb complex, leaving the MutSa complex (MSH2/MSH6) unaffected. 49 As 4-nt insertion loops are mainly suppressed by the MSH2/MSH3 branch of MMR, these could effectively be introduced into Msh3-deficient ESCs, 48 whereas nucleotide substitutions were still suppressed by the activity of the MSH2/MSH6 complex. 8 On the other hand, Msh6-deficiency only allowed the introduction of 1-, 2-, 3-and 4-nt substitutions, while nucleotide insertions were still suppressed by the activity of the remaining MSH2/MSH3 complex. 8 Similarly, Kow et al. 50 reported that +7 nt insertions could efficiently be introduced into an msh3-deficient yeast strain, while +1 nt insertions were suppressed by residual MSH2/MSH6 activity. Conversely, msh6-deficient cells were permissive for +1 nt insertions, while +7 nt insertions were suppressed. The targeting frequencies of the insertion ssODNs in the Msh3-deficient ESC line 48 and the substitution ssODNs in the Msh6-deficient ESC line 8 were on average fivefold lower compared with those in the Msh2-deficient ESCs. This could be explained by the partial redundancy of MutSa and MutSb: the MSH2/MSH3 complex may suppress nucleotide substitutions to some extent in an Msh6-deficient background, whereas the MSH2/MSH6 complex may modestly suppress nucleotide insertions in an Msh3-deficient background.
Temporary MMR suppression allows effective gene targeting
Although MMR deficiency strongly improved the efficacy of ssODNmediated gene targeting, general application may be hampered by the Oligonucleotide-directed gene modification in mouse embryonic stem cells M Aarts and H te Riele mutator phenotype associated with constitutive MMR deficiency (Table 2) . 41, [51] [52] [53] [54] [55] It has been postulated that mismatches that are poorly detected by the MMR system could be introduced into MMRproficient cell lines with a reasonable efficacy. 48 Indeed, ssODNs encoding complex mismatches, such as 3-or 4-nt substitutions and 4-nt insertions, led to detectable levels of gene alteration in wild-type ESCs, but frequencies were still rather low (B10 À6 ) and general rules for ssODN design could not be established. Alternatively, temporary inhibition or downregulation of MMR proteins may limit the mutagenic effects of MMR deficiency. In E. coli, a short-time treatment with the adenine analog 2-aminopurine increased the targeting frequency in a MMR-proficient strain by approximately 10-fold, which was approximately 10-fold lower than that in a MMR-deficient strain. 21 Transient downregulation of MMR expression by RNA interference may also generate a time window that allows effective gene alteration by ssODNs, while preventing the accumulation of inadvertent mutations. Transient knockdown of MSH2 by vector-based RNAi for 4-5 days in mouse ESCs allowed the introduction of 4-nt substitutions with frequencies that were comparable with those in Msh2-deficient cells. 8 MMR function was not completely abrogated in these cells: approximately 10% of residual MSH2 activity remained and was sufficient to suppress simple nucleotide substitutions and nucleotide insertions ( Table 2 ). The mutator phenotype, assessed by the occurrence of slippage errors in simple sequence repeats, was slightly elevated but remained far below that in constitutively MMR-defective cells, as has been demonstrated previously for an Msh2 low ESC line carrying a hypomorphic Msh2 allele. 56 Reducing MMR capacity may also stimulate 'off-target effects' , that is, integration of (part of) the ssODN into the genome at non-homologous sites. Thus far, no unexpected phenotypes have been observed that could be ascribed to inadvertent mutations or illegitimate ssODN integration. It is also important to note that the genetically modified ESCs, which were obtained after transient downregulation of MSH2 retained pluripotency and were able to contribute to the mouse germ line, resulting in the generation of mutant mice. 8 Nonetheless, full insight into the severity of unwanted mutagenesis has to await whole genome sequencing of ssODN-modified ESC. In other mammalian cell lines, such as mouse embryonic fibroblasts, 45 CHO-K1 cells 57 and mixed myoblast/fibroblast cultures, 58 transient downregulation of MSH2 by siRNA led to a twofold increased targeting frequency, whereas in human hepatocytes, stable knockdown of MSH2 increased the targeting frequency 20-to 35-fold. 59 In addition, inducible repression of hMLH1 resulted in a threefold increase in targeting frequency in a doxycycline-regulatable HEK293T La cell line. 6 Although MMR downregulation consistently resulted in increased targeting frequencies, the extent of the increase varied between the different studies. Evidently, this variation could be explained by differences in the degree of knockdown that had been achieved. Moreover, residual MMR activity may suppress certain types of nucleotide alterations more efficiently than others. As we have demonstrated previously, low levels of MMR activity were sufficient to suppress simple nucleotide substitutions and insertions, whereas larger nucleotide substitutions were no longer detected. 8 Recently, McLachlan et al. 60 demonstrated that overexpression of MSH3, which sequesters MSH2 away from MSH6, did not affect the efficacy of 1 nt substitution ssODNs. It is likely that low levels of MSH2/MSH6 complexes were still present and responsible for the suppression of 1 nt substitutions. Together, these data suggest that transient downregulation of MMR genes in combination with specific types of sequence alterations (Table 2 ) is a feasible approach to improve ssODN-mediated gene targeting frequencies in a variety of cell lines.
Consequences of ssODN-mediated gene targeting on cell viability
Chemical modifications such as phosphorothioate (PTO) linkages, 46 or locked nucleic acids, 61 have been added to protect the ssODNs against nucleolytic degradation. However, besides improving the bioavailability of ssODNs, chemical modifications also have deleterious side effects. Olsen et al. 25 demonstrated that the majority of cells that were initially corrected by PTO-modified ssODNs arrested in the G 2 phase of the cell cycle and were rapidly diluted by the proliferating uncorrected cells in the population. This G 2 arrest was due to the presence of unrepaired genomic double-stranded DNA breaks, leading to the activation of the ATM/ATR pathway and phosphorylation of histone H2AX. 6, 62, 63 Although the mechanism underlying this ssODN-mediated toxicity is still largely unknown, the observed DNA damage response seemed to be induced particularly by ssODNs containing protective PTO linkages. 19 Several attempts have been made to counteract the apparent loss of targeted cells due to DNA damage caused by chemically-modified ssODNs. Papaioannou et al. 57 demonstrated that the position of the protective PTO linkages differentially affected the cellular response. The G 2 arrest was less pronounced when cells were exposed to ssODNs carrying internal PTO linkages as opposed to ssODNs that were end-protected by PTO linkages. In this study, it was shown that gene correction by locked nucleic acid-protected ssODNs induced a similar accumulation of cells in G 2 as PTO-protected ssODNs. 57 On the other hand, Andrieu-Soler et al. 61 reported that gene correction by locked nucleic acid-modified ssODNs did not preclude clonal expansion of the corrected cells. Other strategies were based on inhibition of the proliferating non-corrected cells by thymidine, 64 or monastrol, 65 to prevent dilution of the arrested corrected cells in the total population. Although these treatments seemed to enrich for corrected cells, actual recovery of these cells may be hampered by the senescent state that was induced by prolonged thymidine treatment. 64 Rather than counteracting the toxic side effects of PTO-modified ssODNs, the use of unmodified ssODNs may be a more promising strategy for the isolation of viable and stably targeted cells. Recently, we have shown that in mouse ESCs gene correction by PTO-modified ssODN reduced cell viability to 27%, whereas gene correction by unmodified or locked nucleic acid-modified ssODNs allowed 73% of corrected cells to survive. 19 Furthermore, we demonstrated that in contrast to PTO-modified ssODNs, unmodified ssODNs did not induce a substantial amount of double-stranded DNA breaks in corrected and non-corrected ESCs. 19 As a result, unmodified ssODNs yielded higher targeting frequencies than PTO-modified ssODNs in long-term assays, 9,16 although PTO-modified ssODNs initially seemed to be superior in short-term assays. 30, 57 PROSPECTS Challenges for therapeutic application of ssODN-mediated gene targeting The possibility to site-specifically alter endogenous genes may make ssODN-mediated gene targeting an attractive tool for therapeutic applications. Thus far, several reports have described successful in vivo ssODN-directed gene modification in mice. Andrieu-Soler et al. 66 demonstrated ssODN-directed correction of the rd1 point mutation in post-mitotic photoreceptor cells of rd1 mutant mice. Although gene correction promoted cell survival, the number of corrected photoreceptor cells remained insufficient to obtain clinical improvement. Bertoni et al. 67 showed that intramuscular ssODN injection resulted in correction of the mdx 5cv splice site mutation in the dystrophin gene, leading to stable dystrophin expression in muscle fibers for Oligonucleotide-directed gene modification in mouse embryonic stem cells M Aarts and H te Riele up to 3 months. However, muscle cells are multinucleated syncytia and dystrophin expression from a single nucleus may only protect a small region of the fiber. Therefore, the rescue of a single muscle fiber requires the correction of multiple nuclei along the length of the fiber, which may be difficult to achieve because of the low targeting efficiencies. In these examples, ssODN-directed gene modification was achieved in terminally differentiated quiescent cells, which may occur through other mechanisms than targeting of in vitro cultured actively replicating cells. Thus, parameters that have been optimized for ssODN-mediated gene targeting in vitro may not be relevant for in vivo applications. On the other hand, a sustained therapeutic benefit may require targeted gene correction in a proliferating stem cell population rather than in differentiated cells with limited life span. However, to achieve this, serious obstacles need to be overcome. First, in vivo delivery of ssODNs to the cell type of interest may be problematical and require much optimization for each cell type specifically. Complexing the ssODNs with receptor ligands may facilitate organ-or tissue-specific delivery of ssODNs. For example, the carrier YEEE-K 18 , which is a ligand for the asialoglycoprotein receptor tagged with a polylysine chain, has been used to target ssODNs to the liver and kidney of mice by tail-vein injection. 68 However, it is uncertain whether this approach would also improve delivery of ssODNs to a stem cell population. A second problem is the low targeting frequency. With the current frequencies, at least 10 6 cells need to receive ssODNs in order to obtain a few modified cells. These conditions could easily be met in cell culture experiments, but might be nearly impossible in a living organism. Furthermore, a sustained beneficial effect of a few corrected stem cells may only be accomplished when these cells have acquired a proliferative advantage over non-corrected mutant cells. This would restrict this type of therapy to degenerative diseases. Lastly, the suppression of MMR activity, which is required for effective ssODN-mediated gene targeting in many cell types in vitro, may raise a strong impediment to gene therapeutic applications. At the moment, the level of undesired mutations accumulating in ssODN-modified cells during the brief period of MMR suppression has not been determined, and it is unclear whether these mutations would predispose cells to tumor formation. These issues need to be addressed in detail before this technology can enter into a clinical setting. As for all therapies, toxicity and risk of the treatment will have to be balanced with the severity of the disease and the prognosis of the patient. The development of specific MMR inhibitors could greatly restrict the adverse effects of temporary MMR inhibition, thereby facilitating the application of ssODN-mediated gene targeting.
Ex vivo gene therapy by ssODN-mediated gene targeting
The hurdles to in vivo gene correction may shift the focus of future research towards ex vivo application of ssODN-mediated gene modification. Gene correction may be achieved in ex vivo-cultured stem cells, which may subsequently be used to reconstitute a diseased cell compartment in vivo. This scenario of regenerative medicine has recently gained enormous promise by the exciting discovery of Yamanaka and coworkers that differentiated human somatic cells can be reprogrammed into a pluripotent stem cell state, which closely resembles that of ESCs. 69 Induced pluripotent stem cells can be derived from somatic cells upon ectopic expression of four reprogramming factors, Oct4, Klf4, Sox2 and c-Myc. 69 The induced pluripotent stem cells resemble ESCs in many aspects, including morphology, growth characteristics and pluripotency, that is, the capacity to undergo directed differentiation into specific cell types. The therapeutic potential of induced pluripotent stem cells would greatly benefit from the development of efficient techniques for site-specific correction of genetic defects. The in-depth insight into the parameters governing ssODN-directed gene modification in ESCs obtained during the past years may pave the way for customized gene therapy using induced pluripotent stem cells.
CONCLUDING REMARKS
Over the last decade, significant advance has been made in unraveling the basal mechanisms of ssODN-mediated gene targeting. The finding that DNA replication has a crucial role in the coordination of the targeting reaction in bacteria, 20, 21 yeast 23, 24 and various mammalian cell lines including ESCs, 16, 25, 26 has been a major breakthrough. However, ssODN-mediated gene targeting may also occur through other mechanisms. Therefore, reaction parameters may need to be identified and optimized for each cell type specifically. Importantly, the cellular response to ssODN-mediated gene targeting is currently gaining more attention. Issues regarding cell viability and mutagenesis due to MMR inhibition, which may represent a serious bottleneck for wide application of the technique, need to be addressed. Future research may contribute to a better understanding of the capabilities and limitations of site-specific sequence gene modification directed by ssODNs and reveal whether this technique could potentially be applied for the treatment of human genetic disease.
